a

Clinical Studies

Magmaris® RMS’ clinical body of evidence keeps growing with new data from BIOSOLVE-IV of the first cohort with 1,075 patients at 12 months follow-up.

BIOSOLVE-IV

12-month follow-up of first cohort with 1,075 patients1

BIOSOLVE-IV registry - Results of the first cohort of 1,075 patients

Stefan Verheye, MD, presents the outcomes of BIOSOLVE-IV at 12 months.

BIOSOLVE-IV TLF rate
BIOSOLVE-IV registry - Results of the first cohort of 1,075 patients

Stefan Verheye, MD, presents the outcomes of BIOSOLVE-IV at 12 months.

1. Verheye S. Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First Cohort Subjects at 12-month Follow-up of the BIOSOLVE-IV Registry. Presented at: TCT; September 25, 2019; San Francisco; USA. NCT02817802; (n = 2054; 1075 patients presented); 2. TLF is defined as a composite of Cardiac Death and unknown death, Target-Vessel Myocardial Infarction (TV-MI), Clinically-Driven Target Lesion Revascularization (CD-TLR) and emergent CABG; Peri-procedural MI according to SCAI definition and spontaneous MI according to the Extended Historical definition.


​​​​​​​Magmaris is a trademark or registered trademark of the BIOTRONIK Group of Companies.

© 2021 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.